Janssen's Drug Pricing Report Emphasizes Value Of Rebates

As political pressure on pricing continues to build, Janssen's first-ever transparency report notes average list price increase was 8.5% in 2016; annual pricing parties are no longer 'raves,' Raymond James & Associates says.

US-Money-and-Pills_V2_1200x675

More from Pricing Debate

More from Market Access